Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.60 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839926 | 0.84 | MEN1 (0.69) | RAB9AMAPTMAPK1MEN1ALDH1A1 | |
| SCHEMBL3616219 | 0.84 | MAPT (0.57) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL2091634 | 0.82 | CYP1A2 (0.71) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL12810424 | 0.81 | MAPT (0.61) | SMN1; SMN2RAB9AMAPTMAPK1MEN1 | |
| SCHEMBL9342841 | 0.81 | MAPK1 (0.68) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL12015657 | 0.80 | ALDH1A1 (0.66) | SMN1; SMN2MAPTMAPK1MEN1ALDH1A1 | |
| SCHEMBL16270240 | 0.80 | LMNA (0.55) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL10428818 | 0.80 | NPC1 (0.74) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL2095656 | 0.79 | FAAH (0.68) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7260444 | 0.79 | MAPT (0.75) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160023997-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160023997-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150080301-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080301-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | BEZWADA BIOMEDICAL LLC (US) | 2015-03-19 | — | — | US | disclosed |
| US-8901347-B1 | Absorbable polyurethanes and methods of use thereof | BEZWADA BIOMEDICAL, LLC (US) | 2014-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080301-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | HPGDS, ITGAM, P4HTM | SMN1; SMN2 2468/4885NPC1 2309/4885RAB9A 2652/4885 |
| US-20160023997-A1 | ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF | HPGDS, ITGAM, P4HTM | SMN1; SMN2 2468/4885NPC1 2309/4885RAB9A 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.